Rockefeller Capital Management L.P. Purchases 25,254 Shares of Amgen Inc. $AMGN

Rockefeller Capital Management L.P. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 522,925 shares of the medical research company’s stock after buying an additional 25,254 shares during the quarter. Rockefeller Capital Management L.P. owned 0.10% of Amgen worth $146,006,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Nuveen LLC acquired a new stake in shares of Amgen in the first quarter valued at approximately $688,868,000. Federated Hermes Inc. boosted its holdings in Amgen by 48.5% during the first quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after purchasing an additional 665,555 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Amgen by 128.9% in the first quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock valued at $332,017,000 after purchasing an additional 600,096 shares in the last quarter. WoodTrust Financial Corp increased its stake in Amgen by 8,223.6% in the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company’s stock valued at $166,307,000 after buying an additional 588,478 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Amgen in the 2nd quarter valued at $156,812,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on AMGN. Morgan Stanley reduced their price objective on shares of Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Piper Sandler increased their price target on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research report on Friday. The Goldman Sachs Group decreased their price target on Amgen from $405.00 to $400.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Wells Fargo & Company upped their price objective on Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Finally, Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $314.05.

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 9,036 shares of company stock valued at $2,992,594 in the last quarter. Company insiders own 0.76% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $336.74 on Friday. The stock has a 50 day simple moving average of $294.91 and a 200 day simple moving average of $290.40. The stock has a market cap of $181.33 billion, a P/E ratio of 27.53, a PEG ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $345.84. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter last year, the business earned $5.58 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 2.8%. Amgen’s payout ratio is 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.